ArticlePregnancy (Hoboken, N.J.)2026
Association of maternal height with pregnancy complications: Analyses of two cohorts.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Height is inversely associated with risk of cardiovascular and metabolic conditions in nonpregnant populations. Whether maternal height is independently associated with pregnancy complications, after accounting for prepregnancy weight, remains less clear. Objective: To investigate associations of maternal height with pregnancy complications, independent of prepregnancy weight, and to examine the role of infant sex and race/ethnicity in these associations. Methods: We conducted a secondary analysis of data from the Omega and Hyperglycemia and Adverse Pregnancy Outcome (HAPO) prospective cohort studies of pregnant women (total Results: Each 5-cm greater maternal height was associated with lower GDM risk in both cohorts, with a modest association in Omega and a larger association in HAPO (Omega: adjusted RR [aRR], 0.99; 95% CI, 0.98, 0.99; HAPO: aRR, 0.84; 95% CI, 0.78, 0.90). Short women had higher GDM risk (Omega: aRR, 1.05; 95% CI, 1.03, 1.07; HAPO: aRR, 1.44; 95% CI, 1.18, 1.75), and tall women had lower GDM risk (Omega: aRR, 0.98; 95% CI, 0.96, 0.99; HAPO: aRR, 0.71; 95% CI, 0.56, 0.89), compared with women with average height. In Omega, linear height was associated with slightly lower preeclampsia risk (aRR, 0.99; 95% CI, 0.99, 0.99) and slightly greater PTB risk (aRR, 1.01; 95% CI, 1.00, 1.01). Infant sex or race/ethnicity did not meaningfully modify the association between height and GDM in either cohort. Conclusion: Maternal height was inversely associated with GDM risk in both cohorts. We also observed small, cohort-specific associations of height with PTB and preeclampsia in Omega. These findings suggest that maternal height may provide modest information beyond conventional maternal body-size measures, although its clinical utility for individual risk prediction or targeted monitoring may be limited and requires further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.